A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Galinpepimut S (Primary) ; Nivolumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 04 Aug 2016 Status changed from suspended to recruiting.
- 01 Aug 2016 Status changed from recruiting to suspended.
- 19 Apr 2016 New trial record